Actively Recruiting
Psilocybin for Methamphetamine Addiction
Led by Kevin Murnane · Updated on 2025-10-07
20
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.
CONDITIONS
Official Title
Psilocybin for Methamphetamine Addiction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 25 to 65 years at time of informed consent
- Methamphetamine is the drug of choice
- Score of 3 or higher on the Severity of Dependence Scale
- Have been at the designated local treatment facility for at least 7 days
- Used methamphetamine in the month before admission to the treatment center
- Desire to stop methamphetamine use aiming for complete abstinence
- English speaking, as all neuropsychological tasks are in English
- No psychedelic use or at least 3 years since last psychedelic use
- Able to attend two telehealth and one in-person preparatory sessions
- Able to attend two telehealth integration sessions and three follow-up assessments
- Diagnosed with Stimulant Use Disorder - Amphetamine type, with no other substance dependence except nicotine or cannabis
- In acute remission from methamphetamine for at least 7 days before drug administration, confirmed by self-report and urine drug screen
You will not qualify if you...
- Dependence on other substances besides methamphetamine, nicotine, or cannabis
- History of Hallucinogen Use Disorder or Hallucinogen Persisting Perceptive Disorder
- Women who are pregnant, planning pregnancy, or breastfeeding
- Women not agreeing to abstinence or not using dual contraception during the study
- Current hypertension exceeding 140/90 mmHg at screening or pre-dosing
- Heart rate below 60 bpm or above 100 bpm at screening or pre-dosing
- QTc interval less than 350 msec or greater than 460 msec
- History of cardiovascular or cerebral vascular disease (except controlled hypertension)
- Unstable medical or psychiatric conditions as determined by psychiatrist
- Diagnosis of schizophrenia or type 1 bipolar disorder
- Recent or current suicidal thoughts in last 6 months
- Taking prohibited medications or unwilling/unable to stop them
- History of significant brain injury or seizure disorder
- Inability to understand informed consent or study materials
- Moderate to severe liver impairment
- Planning to move away from Shreveport-Bossier area within 6 months
- Significant abnormalities in blood tests outside defined clinical ranges
- Medications antagonizing serotonin 2A receptor, serotonergic drugs, UGT1A9/10 inhibitors, MAOIs, or aldehyde/alcohol dehydrogenase inhibitors not discontinued at least 5 half-lives before dosing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
LSU Health Shreveport
Shreveport, Louisiana, United States, 71103
Actively Recruiting
Research Team
K
Kevin S Murnane, PhD
CONTACT
J
John A Vanchiere, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here